These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 27917551)

  • 1. Comments on 'Estimands in clinical trials - broadening the perspective'.
    Permutt T
    Stat Med; 2017 Jan; 36(1):20-21. PubMed ID: 27917551
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on 'Estimands in clinical trials - broadening the perspective'.
    Rockhold F
    Stat Med; 2017 Jan; 36(1):24-26. PubMed ID: 27917552
    [No Abstract]   [Full Text] [Related]  

  • 3. Comments on 'Estimands in clinical trials - broadening the perspective'.
    Bauer P
    Stat Med; 2017 Jan; 36(1):22-23. PubMed ID: 27917555
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimands: discussion points from the PSI estimands and sensitivity expert group.
    Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
    Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choosing estimands in clinical trials with missing data.
    Mallinckrodt C; Molenberghs G; Rathmann S
    Pharm Stat; 2017 Jan; 16(1):29-36. PubMed ID: 27492760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimands in clinical trials - broadening the perspective.
    Akacha M; Bretz F; Ruberg S
    Stat Med; 2017 Jan; 36(1):5-19. PubMed ID: 27435045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
    Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
    Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimands: A More Strategic Approach to Study Design and Analysis.
    Akacha M; Kothny W
    Clin Pharmacol Ther; 2017 Dec; 102(6):894-896. PubMed ID: 29119556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comments on "A taxonomy of estimands for regulatory clinical trials with discontinuations".
    Doi M; Watanabe D; Takenouchi K; Tsuchikawa M
    Stat Med; 2017 Nov; 36(27):4414-4416. PubMed ID: 29110371
    [No Abstract]   [Full Text] [Related]  

  • 10. A structured approach to choosing estimands and estimators in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Lipkovich I; Molenberghs G
    Pharm Stat; 2012; 11(6):456-61. PubMed ID: 22962024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary: Estimands in cluster trials: thinking carefully about the target of inferenceand the consequences for analysis choice.
    Hemming K; Taljaard M
    Int J Epidemiol; 2023 Feb; 52(1):116-118. PubMed ID: 36018244
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary for the Missing Data Working Group's perspective for regulatory clinical trials, estimands, and sensitivity analyses.
    Koch GG; Wiener LE
    Stat Med; 2016 Jul; 35(17):2887-93. PubMed ID: 27374356
    [No Abstract]   [Full Text] [Related]  

  • 13. Endpoints and estimands: understanding trials of weight-loss drugs.
    Adler AI
    Nat Med; 2022 Oct; 28(10):2005-2006. PubMed ID: 36216946
    [No Abstract]   [Full Text] [Related]  

  • 14. Disentangling estimands and the intention-to-treat principle.
    Leuchs AK; Brandt A; Zinserling J; Benda N
    Pharm Stat; 2017 Jan; 16(1):12-19. PubMed ID: 27910217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comments on "Some Challenges with Statistical Inference in Adaptive Designs" by Hung, Wang, and Yang.
    Mehta CR
    J Biopharm Stat; 2016; 26(2):402-4. PubMed ID: 26428953
    [No Abstract]   [Full Text] [Related]  

  • 16. Comments on the debate between marginal and conditional estimands.
    Spieker AJ
    Stat Med; 2022 Dec; 41(28):5589-5591. PubMed ID: 36385475
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C; Beltangady M
    J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments on the FDA draft guidance on adaptive designs.
    Wittes J
    J Biopharm Stat; 2010 Nov; 20(6):1166-70. PubMed ID: 21058112
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: Estimands in clinical trials - a challenge to intention to treat?
    Day S
    Stat Med; 2017 Jan; 36(1):3-4. PubMed ID: 27917553
    [No Abstract]   [Full Text] [Related]  

  • 20. Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials.
    Mehrotra DV; Hemmings RJ; Russek-Cohen E;
    Clin Trials; 2016 Aug; 13(4):456-8. PubMed ID: 26908545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.